# TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

> **NCT07047365** · PHASE3 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 416 (estimated)

## Conditions studied

- HER2-positive Advanced Breast Cancer

## Interventions

- **DRUG:** TQB2930+ chemotherapy
- **DRUG:** Trastuzumab+ chemotherapy

## Key facts

- **NCT ID:** NCT07047365
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07047365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07047365, "TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07047365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*